cancer vaccine

Focus magnify target strategy
Biotech

Nykode bets future on cancer trial after losing Genentech pact

While the axing of the Genentech deal was the initial blow, Nykode is also contending with the potential loss of future revenues from Regeneron.
Nick Paul Taylor Aug 27, 2025 8:25am
next step ladder climb succeed win

PDS reports 39 months OS in phase 2 head and neck cancer trial

Aug 25, 2025 9:00am
dart board miss failure

Cancer vaccine's 'narrow' fail won't stop IO heading to FDA

Aug 11, 2025 9:48am
arrow choose one big pick forward many

Scancell picks winner from phase 2 cancer vaccine face-off

Jul 22, 2025 9:38am
layoffs job cuts fired exit restructuring layoff reduction

BioNTech's chief strategy officer heads for the exit

Jul 17, 2025 10:55am
medical data concept with hospital in the background

OSE shares 65% OS rate behind cancer vaccine's phase 2 win

Jun 3, 2025 7:05am